Merck and AstraZeneca updates on US regulatory review of Lynparza for mCRPC

AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.

ProBioGen’s growth strategy continues successfully

Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team

LifeSigns launches smart ward with wireless patient monitoring technology

Amala Hospital partners with LifeSigns to provide revolutionary technology for the first time in the State

AstraZeneca expands its portfolio by bringing rare disease therapy for patients in India

Receives regulatory approval for its molecule ‘Selumetinib’ in India

NATCO launches generic Pomalidomide Capsules in Canada

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules

ENHERTU approved in China for patients with HER2 positive metastatic breast cancer treated withantiHER2-based regimens

First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China

Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi

The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region

CarDekho adds Medulance to provide emergency medical services

Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.